Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study
- PMID: 20570401
- PMCID: PMC2902689
- DOI: 10.1016/j.neurobiolaging.2010.04.030
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study
Abstract
Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Abeta(1-42)) and elevated total tau (t-tau) and phosphorylated tau (p-tau(181p)) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Abeta(1-42), t-tau, and p-tau(181p) and apolipoprotein E (ApoE) epsilon4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Abeta(1-42) and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Abeta(1-42) levels and higher tau levels supports the hypothesis that CSF Abeta(1-42) and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE epsilon4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.
2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
Dr. Aisen has served as a consultant to Pfizer, Merck, and Novartis.
Dr. Schuff received honorary from the Michael J Fox foundation, the British Research Council and Elsevier Publishing company; receives research support from M.J. Fox foundation, Department of Defense (WX), P41 RR023953 (Coinvestigator); P50AG23501 (Coninvestigator).
Dr. Petersen serves as a consultant to Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare; receives royalties from publishing Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIA [AG 06786 (PI) and AG 16574 (PI)].
Dr. Weiner serves on scientific advisory boards for Bayer Schering Pharma, Eli Lilly, Nestle, CoMentis, Neurochem, Eisai, Avid, Aegis, Genentech, Allergan, Lippincott, Bristol Meyers Squibb, Forest, Pfizer, McKinsey, Mitsubishi, and Novartis. He has received non–industry-supported funding for travel; serves on the editorial board of Alzheimer's & Dementia; received honoraria from the Rotman Research Institute and BOLT International; receives research support from Merck & Co, Avid, NIH [U01AG024904 (PI), P41 RR023953 (PI), R01 AG10897 (PI), P01AG19724 (Coinvestigator), P50AG23501(Coinvestigator), R24 RR021992 (Coinvestigator), R01 NS031966 (Coinvestigator), and P01AG012435 (Coinvestigator)], the Department of Defense [DAMD17-01-1-0764 (PI)], and the Veterans Administration [MIRECC VISN 21 (Core PI)]; and holds stock in Synarc and Elan Pharmaceuticals.
Figures




Similar articles
-
Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.J Alzheimers Dis. 2011;26 Suppl 3(0 3):77-90. doi: 10.3233/JAD-2011-0006. J Alzheimers Dis. 2011. PMID: 21971452 Free PMC article.
-
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13. AJNR Am J Neuroradiol. 2013. PMID: 22976236 Free PMC article.
-
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953. Ann Neurol. 2010. PMID: 20373342 Free PMC article.
-
The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology.Alzheimers Res Ther. 2017 Apr 26;9(1):31. doi: 10.1186/s13195-017-0258-6. Alzheimers Res Ther. 2017. PMID: 28441961 Free PMC article. Review.
-
Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.Neurobiol Aging. 2014 Sep;35 Suppl 2(Suppl 2):S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Epub 2014 May 15. Neurobiol Aging. 2014. PMID: 24973118 Free PMC article. Review.
Cited by
-
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.Alzheimers Dement. 2010 May;6(3):212-20. doi: 10.1016/j.jalz.2010.03.004. Alzheimers Dement. 2010. PMID: 20451869 Free PMC article. Review.
-
Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging.Future Neurol. 2015 Jan 1;10(1):49-65. doi: 10.2217/fnl.14.60. Future Neurol. 2015. PMID: 25774094 Free PMC article.
-
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170. Front Biosci (Landmark Ed). 2013. PMID: 23747874 Free PMC article. Review.
-
What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.Prog Neurobiol. 2014 Jun;117:20-40. doi: 10.1016/j.pneurobio.2014.02.004. Epub 2014 Feb 16. Prog Neurobiol. 2014. PMID: 24548606 Free PMC article. Review.
-
Apolipoprotein E ɛ4-related effects on cognition are limited to the Alzheimer's disease spectrum.Geroscience. 2022 Feb;44(1):195-209. doi: 10.1007/s11357-021-00450-x. Epub 2021 Sep 30. Geroscience. 2022. PMID: 34591236 Free PMC article.
References
-
- Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Arch Neurol. 2008;65:1509–1517. - PMC - PubMed
-
- Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, Lindau M, Eriksdotter-Jonhagen M. Differential CSF Biomarker Levels in APOE- e4-Positive and -Negative Patients with Memory Impairment. Dementia and Geriatric Cognitive Disorders. 2007;23:87–95. - PubMed
-
- Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Cerebrospinal fluid tau and A[beta]42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters. 1999;273:5–8. - PubMed
-
- Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease. Cereb Cortex. 1991;1:103–116. - PubMed
-
- Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology of Aging. 2006;27:1416–1424. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 AG030514/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- R01 NS031966/NS/NINDS NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- R01 AG010897/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- P01 AG012435/AG/NIA NIH HHS/United States
- P41 RR023953/RR/NCRR NIH HHS/United States
- U24 RR021992/RR/NCRR NIH HHS/United States
- T32 EB001631/EB/NIBIB NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous